Aerie Pharmaceuticals, Inc (AERI)

Etorro trading 970x250
Aerie Pharmaceuticals, Inc (AERI) Logo

About Aerie Pharmaceuticals, Inc

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina. Address: 4301 Emperor Boulevard, Durham, NC, United States, 27703

Aerie Pharmaceuticals, Inc News and around…

Latest news about Aerie Pharmaceuticals, Inc (AERI) common stock and company :

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
12 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We're getting right into the thick of it today with a look at the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
12 Oct, 2021 FinancialContent

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline results for the Company’s Phase 3 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% (“netarsudil 0.02%”) versus ripasudil hydrochloride hydrate ophthalmic solution 0.4% (“ripasudil 0.4%”). The results showed that netarsudil 0.02% once daily was superior to ripasudil 0.4% twice daily in lowering intraocular pressure (“IOP”) at week four (p

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
10 Oct, 2021 FinancialContent

Biotech stocks retreated in the week endingOct. 8, extending losses for the third straight week. Some of the selling in the space ...

Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
07 Oct, 2021 FinancialContent

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aerie’s retina product candidates, at the Ophthalmology Innovation Summit Retina Innovation Showcase. The slide presentation addresses Aerie’s proprietary PRINT® drug delivery platform and retina product candidates AR-1105 (dexamethasone implant, Phase 3 ready), AR-13503 (Rho kinase/Protein kinase C inhibitor implant, Phase 2a), and AR-14034 (pan-VEGF receptor inhibitor implant, preclinical).

The Math Shows XPH Can Go To $72
07 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $71.78 per unit.

Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
06 Oct, 2021 FinancialContent

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal implant) Phase 2 clinical trial in patients with macular edema due to retinal vein occlusion will be presented at the 39th Annual Scientific Meeting of the American Society of Retina Specialists in San Antonio, Texas.

Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
27 Sep, 2021 FinancialContent

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin F. McGraw, III, Pharm.D., Interim Executive Chairman and David A. Hollander, M.D., M.B.A., Chief R&D Officer, will participate in a fireside discussion at the virtual Cantor Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40 a.m. Eastern Time. Dr. McGraw and Dr. Hollander will provide an Aerie overview and business update.

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
21 Sep, 2021 FinancialContent

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021, Vicente Anido, PhD. no longer serves as the Company’s Chairman and Chief Executive Officer or as a director of the Company. Consistent with the succession plan in place, the Company’s Board of Directors has appointed Benjamin F. McGraw, III, Pharm.D. as its Interim Executive Chairman of the Board of Directors of the Company and commenced a search for a new Chief Executive Officer. Upon the appointment of a new Chief Executive Officer, the Company intends to separate the roles of Chairman and Chief Executive Officer.

Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
20 Sep, 2021 FinancialContent

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment Erik Pacyniak, Ph.D., D.A.B.T., Director, Toxicology, reporting to Jeff White, Ph.D., D.A.B.T., Aerie’s Vice President of Research and Discovery. Dr. Pacyniak will oversee all aspects of nonclinical toxicology and drug disposition for Aerie. He most recently held a related nonclinical safety assessment position at Mycovia Pharmaceuticals, Inc.

Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win
17 Sep, 2021 Yahoo! Finance

AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.

56 Biggest Movers From Yesterday
17 Sep, 2021 FinancialContent

Check out these big penny stock gainers and losersLosers Vera Therapeutics, Inc. (NASDAQ: VERA) shares tumbled ...

Why The Future Is Cloudy For This Aerie Pharmaceuticals Drug As Shares Plummet
16 Sep, 2021 FinancialContent

Aerie Pharmaceuticals missed the mark in a dry-eye disease test, leading AERI stock to plummet to a 10-month low Thursday.

Mid-Afternoon Market Update: Dow Falls 70 Points; Aerie Pharmaceuticals Shares Plunge
16 Sep, 2021 FinancialContent

Toward the end of trading Thursday, the Dow traded down 0.20% to 34,745 while the NASDAQ fell 0.03% to 15,157.61. The S&P also fell, ...

12 Health Care Stocks Moving In Thursday's Intraday Session
16 Sep, 2021 FinancialContent

Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 27.72% to $2.46 during Thursday's regular session. As ...

Mid-Day Market Update: Gold Drops Over 2%; Leap Therapeutics Shares Jump
16 Sep, 2021 FinancialContent

Midway through trading Thursday, the Dow traded down 0.74% to 34,557.75 while the NASDAQ fell 0.67% to 15,060.25. The S&P also fell, ...

38 Stocks Moving In Thursday's Mid-Day Session
16 Sep, 2021 FinancialContent

Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) shares jumped 30.4% to $41.90 amid increased retail investor interest in the ...

Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study
16 Sep, 2021 Yahoo! Finance

Aerie Pharmaceuticals (AERI) reports mixed data from the phase IIb study evaluating AR-15512 for treating dry eye disease. Resultantly, the stock declines in after-market trading on Sep 15.

Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in August
16 Sep, 2021 FinancialContent

Following the market opening Thursday, the Dow traded down 0.45% to 34,657.69 while the NASDAQ fell 0.66% to 15,061.97. The S&P also ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
16 Sep, 2021 FinancialContent

Gainers Leap Therapeutics (NASDAQ:LPTX) stock rose 32.64% to $2.56 during Thursday's pre-market session. The ...

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

20 Stocks Moving in Thursday's Pre-Market Session
16 Sep, 2021 FinancialContent

Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) rose 59.7% to $51.30 in pre-market trading. IronNet Cybersecurity emerged as ...

Aerie Pharma Reports Mixed Bag On Phase 2 Dry Eye Trial
16 Sep, 2021 FinancialContent

Aerie Pharmaceuticals Inc(NASDAQ: AERI)announced topline resultsof its Phase 2b COMET-1 study evaluating AR-15512 ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
15 Sep, 2021 FinancialContent

Gainers Larimar Therapeutics (NASDAQ:LRMR) shares rose 10.53% to $13.75 during Wednesday's after-market session. The ...

Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b C
15 Sep, 2021 FinancialContent

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive topline results of its Phase 2b clinical study, named COMET-1, for AR-15512 (TRPM8 Agonist) (“AR-15512”) ophthalmic solution for the treatment of patients with dry eye disease. Management will host a conference call and provide accompanying slides to discuss these results at 5:00 p.m. ET today.

Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease
15 Sep, 2021 Yahoo! Finance

DURHAM, N.C., September 15, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive topline results of its Phase 2b clinical study, named COMET-1, for AR-15512 (TRPM8 Agonist) ("AR-15512") ophthalmic solution for the treatment of patients with dry eye dise

Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
13 Sep, 2021 FinancialContent

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Carolyn McAuliffe, Senior Director, Communications, reporting to Tad Heitmann, Aerie’s Vice President of Marketing. Ms. McAuliffe will be responsible for the development and execution of Aerie’s marketing and medical communications activities. She most recently held a related position at Masimo Corporation.

Notable Thursday Option Activity: WKHS, GPS, AERI
09 Sep, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Workhorse Group Inc (WKHS), where a total of 55,041 contracts have traded so far, representing approximately 5.5 million underlying shares. That amounts to about 67.9% of WKHS's average daily trading volume over the past month of 8.1 million shares..

Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
07 Sep, 2021 FinancialContent

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will participate in the following virtual investor conferences.

Aerie Pharmaceuticals, Inc (AERI) is a NASDAQ Common Stock listed in , ,

970x250